Show simple item record

dc.contributor.authorWolleschak, Denise
dc.contributor.authorMack, Thomas S
dc.contributor.authorPerner, Florian
dc.contributor.authorFrey, Stephanie
dc.contributor.authorSchnöder, Tina M
dc.contributor.authorWagner, Marie-Christine
dc.contributor.authorHöding, Christine
dc.contributor.authorPils, Marina C
dc.contributor.authorParkner, Andreas
dc.contributor.authorKliche, Stefanie
dc.contributor.authorSchraven, Burkhart
dc.contributor.authorHebel, Katrin
dc.contributor.authorBrunner-Weinzierl, Monika
dc.contributor.authorRanjan, Satish
dc.contributor.authorIsermann, Berend
dc.contributor.authorLipka, Daniel B
dc.contributor.authorFischer, Thomas
dc.contributor.authorHeidel, Florian H
dc.date.accessioned2014-08-21T10:32:29Zen
dc.date.available2014-08-21T10:32:29Zen
dc.date.issued2014-06en
dc.identifier.citationClinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. 2014, 99 (6):e90-3 Haematologicaen
dc.identifier.issn1592-8721en
dc.identifier.pmid24633870en
dc.identifier.doi10.3324/haematol.2014.104331en
dc.identifier.urihttp://hdl.handle.net/10033/325037en
dc.language.isoenen
dc.rightsArchived with thanks to Haematologicaen
dc.titleClinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.en
dc.typearticleen
dc.identifier.journalHaematologicaen
refterms.dateFOA2018-06-12T19:59:05Z


Files in this item

Thumbnail
Name:
Wolleschak et al_final.pdf
Size:
2.276Mb
Format:
PDF
Description:
Open Access Publication

This item appears in the following Collection(s)

Show simple item record